P. J. Lynch

发表

Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy.

Shu-Ching Hsu, D. Prockop, Jeffrey L. Spees, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Ryanodine receptor mutations in malignant hyperthermia and central core disease

T. McCarthy, K. Quane, P. Lynch, 2000, Human mutation.

An Auxiliary Silencer and a Boundary Element Maintain High Levels of Silencing Proteins at HMR in Saccharomyces cerevisiae

L. Rusche, P. Lynch, P. J. Lynch, 2010, Genetics.

A Silencer Promotes the Assembly of Silenced Chromatin Independently of Recruitment

L. Rusche, P. Lynch, P. J. Lynch, 2008, Molecular and Cellular Biology.

Sum1p, the Origin Recognition Complex, and the Spreading of a Promoter-Specific Repressor in Saccharomyces cerevisiae

J. Rine, H. Fraser, L. Rusche, 2005, Molecular and Cellular Biology.

High Basal Levels of γH2AX in Human Induced Pluripotent Stem Cells Are Linked to Replication‐Associated DNA Damage and Repair

B. Mallon, Guibin Chen, Haritha Vallabhaneni, 2018, Stem cells.

Chromatin Changes at the PPAR‐γ2 Promoter During Bone Marrow‐Derived Multipotent Stromal Cell Culture Correlate With Loss of Gene Activation Potential

S. Bauer, D. Hursh, Yazmin I Rovira Gonzalez, 2015, Stem cells.

Differentiation, cell fusion, and nuclear fusion during ex vivo repair of epithelium by human adult stem cells from bone marrow stroma

D. Prockop, Jeffrey L. Spees, S. Olson, 2003, Proceedings of the National Academy of Sciences of the United States of America.

In vitro cytokine licensing induces persistent permissive chromatin at the Indoleamine 2,3-dioxygenase promoter.

D. Hursh, B. Stultz, P. Lynch, 2016, Cytotherapy.

Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions.

P J Lynch, C C Jaffe, P Atkinson, 1996, The American journal of cardiology.

A mutation in the transmembrane/luminal domain of the ryanodine receptor is associated with abnormal Ca2+ release channel function and severe central core disease.

M. Lehane, L. Giblin, D. Maclennan, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Differential gene expression in the striatum of mice with very low expression of the vesicular monoamine transporter type 2 gene

P. M. Chan, P. Emson, R. E. Colebrooke, 2007, Brain Research.

Gene expression profiles of metabolic enzyme transcripts in Alzheimer's disease

M. Starkey, P. Emson, R. Faull, 2007, Brain Research.

Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation.

G. Comi, M. Lehane, A. Urwyler, 1998, American journal of human genetics.

A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.

K. Stowell, T. McCarthy, A. Pollock, 2000, Human molecular genetics.

Molecular aspects of malignant hyperthermia and central core disease

T. McCarthy, P. Lynch, P. J. Lynch, 2000 .

Detection of a novel mutation in the ryanodine receptor gene in an Irish malignant hyperthermia pedigree: correlation of the IVCT response with the affected and unaffected haplotypes.

M. Lehane, K. Keating, T. McCarthy, 1997, Journal of medical genetics.

A Metabolomic Study of Brain Tissues from Aged Mice with Low Expression of the Vesicular Monoamine Transporter 2 (VMAT2) Gene

P. Emson, R. Salek, J. Griffin, 2008, Neurochemical Research.

In vitro cytokine licensing induces persistent permissive chromatin at the Indoleamine 2,3-dioxygenase promoter.

D. Hursh, B. Stultz, Yazmin I Rovira Gonzalez, 2016, Cytotherapy.

Identification of Heterozygous and Homozygous Individuals with the Novel RYR1 Mutation Cys35Arg in a Large Kindred

N. Monnier, J. Lunardi, T. McCarthy, 1997, Anesthesiology.

Novel mutations at a CpG dinucleotide in the ryanodine receptor in malignant hyperthermia

G. Comi, A. Urwyler, J. Lunardi, 1998, Human mutation.